Enveda

Congratulations to @viswacolluru and the @lifeschemistry team on your $150M Series D raise and reaching unicorn status! By combining AI and chemistry, Enveda is opening new paths in biotech and redefining what’s possible in drug development. We are excited to see what’s next as https://t.co/TrSbFHzSF0

Congrats to the entire Enveda (@lifeschemistry) team on their recent $150M Series D raise, coming off several impressive clinical and operational milestones! Looking forward to all the exciting progress from such a prolific platform and deep pipeline of medicines https://t.co/MCJb5LyBU2

$150M Raised: @lifeschemistry Reaches Unicorn Status & Advances Clinical Pipeline! Boulder-based biotech company Enveda has closed an oversubscribed $150 million Series D round led by Premji Invest. The funding, which brings its total raised to $517 million, coincides with major https://t.co/WDkfqX8Kmd

New Raise 🏛️ Company: Enveda 🔗 Website: https://t.co/VupnGWJNRF 📊 Amount: $150 Million 🔄 Round: Series D 🧮 Valuation: N/A ⚙️ Industry: Biotechnology

12. Enveda @lifeschemistry has raised $150 million in a Series D round, reaching unicorn status. The Colorado-based biotech company uses AI & ML to revitalize natural product drug discovery, developing novel drug candidates for complex conditions like atopic dermatitis, asthma, https://t.co/baUDG16iMr